Creative Medical Technology Holdings Inc (CELZ)

[monte379]

This is what the INVESTORS KNOW about CELZ.......but don't trust me or anyone on the blog. Do you own DD please, and you too will KNOW......

The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.

CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PED5 inhibitors, CaverStem® and FemCelz is safe.

Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.

Two shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials will be published soon.

CELZ added physicians in Hawaii (Sanderson), California, Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem® website as they come aboard. CELZ is adding approximately 5 doctors per month in the most recent two months.

To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office to train.

Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.

Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos. These will be posted soon.

CELZ has started treating the first patients with the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program. Doctors have been treating the first patients with FemCelz and additional doctors are scheduled to be trained in FemCelz procedures.

Over 50 domain names have been registered showing that MANY more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.

CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the January emails. Your DD will show you that more interest is building each month.

CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area.

U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.

Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.

A one-year trial has concluded and will PROVE the same results and you can watch it here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14

CELZ is working on their paper for publication. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only.

Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. Evidence of this are the scores of patients treated in Rome and NM. CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.

CELZ has Institutional Investors now, slowing dilution and providing much better terms as CELZ completes the commercialization phase. The most recent notes that were issued in 2018 were renegotiated providing cash for operations.

CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz will generate. This has generated many calls to the vetted doctors.

CELZ anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz brands.

CaverStem® and FemCelz are just TWO of SEVERAL patents held by CMTH.
4 NEW patents were applied for in 2018.

CELZ anticipates commercialization of StemSpine in late 2019 or early 2020 bringing online a third revenue source.

Gershman and Ichim have already successfully commercialized Medistem.

CaverStem®, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
CaverStem is now a REGISTERED TRADEMARK. Caverstem®

We KNOW Caverstem® + FemCelz + StemSpine + AmnioStem = NASDAQ

PLEASE read the sticky posts seen when logging in to iHub through a browser!!